Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion

Part of paid clinical trials in St Louis, Missouri.

Sponsor
Barnes Retina Institute
Study ID
NCT01428388
Status
Completed

Conditions

  • Macular Edema
  • Retinal Vein Occlusion

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Accepted

Interventions

Study Details

Antagonists of the vascular endothelial growth factor (VEGF) pathway are effective in treating macular edema resulting from retinal vein occlusion (RVO). In the eye, the two most widely used anti-VEGF agents are ranibizumab and bevacizumab. Only ranibizumab has been FDA-approved for the treatment of macular edema from RVO, however bevacizumab has been used off-label by many ophthalmologists with good success. Furthermore, the cost of bevacizumab is less than one-tenth the cost of ranibizumab. Here the investigators conduct a six month randomized, prospective interventional trial comparing the effectiveness of ranibizumab with bevacizumab in the treatment of macular edema from RVO. Primary outcome measures are change in central retinal thickness. Secondary measures are change in visual acuity from baseline and change in angiographic properties of macular lesions from baseline after treatment.

Key Dates

First listed
Sep 5, 2011
Start date
Sep 30, 2011
Status verified
Oct 2017
Primary completion
Oct 31, 2015
Completion
Dec 31, 2015

Study Design

Enrollment
150 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Bevacizumab
  • Active Comparator: Ranibizumab

Primary Outcome Measure

change in central retinal thickness [ Time Frame: six months compared to baseline ]

Locations (1)

FacilityCityStateZIPSite coordinators
The Retina InstituteSt LouisMissouri63110-

Find similar trials in St Louis, MO

By research site
The Retina Institute· St Louis, MO

Related Studies